Opendata, web and dolomites

BoVLP-BVD SIGNED

Tagged (DIVA) polyantigenic vaccine against Bovine Viral Diarrhea virus (BVDv) based on virus-Like-Particles

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BoVLP-BVD project word cloud

Explore the words cloud of the BoVLP-BVD project. It provides you a very rough idea of what is the project "BoVLP-BVD" about.

business    point    eradication    internal    25    worldwide    candidate    virus    aquil    animal    antibiotics    774994    commercial    euros    herds    complete       rate    reproduction    hut    demonstrating    economic    ordm    species    agreements    milestones    veterinarian    vivo    exposed    agent    countries    patented    programs    sme    feasibility    oacute    trl8    becomes    endemic    biotech    vaccines    attributes    cattle    persistent    data    suboptimal    manufacturing    fight    demonstrated    diva    bvd    company    royalties    food    infectious    prevent    90    projections    social    bvdv    pharmaceutical    multiplier    industrial    50    agro    vaccine    trl6    million    prototype    positive    productivity    lifetime    stage    reduce    environmental    infection    bovine    hundreds    public    had    viral    systematic    pressure    cyl    approximately    of    livestock    investment    safety    herd    disease    return    commercialisation    vaccination    particle    efficacy    bodies    5x    industry    instrument    diarrhea    diseases    licensed    recombinant    regulatory    animals    context    final   

Project "BoVLP-BVD" data sheet

The following table provides information about the project.

Coordinator
AQUILON CYL SOCIEDAD LIMITADA 

Organization address
address: LUGAR FACULTAD DE VETERINARIA S/N CAMPUS VEGAZANA
city: LEON
postcode: 24000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 2˙221˙042 €
 EC max contribution 1˙554˙729 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AQUILON CYL SOCIEDAD LIMITADA ES (LEON) coordinator 1˙554˙729.00

Map

 Project objective

In a general context of environmental, social and legal pressure to reduce the use of antibiotics to fight diseases in livestock animals, cost-effective vaccination becomes the focus of most of the industry, regulatory and agro-food public bodies. Development of new vaccines to prevent the disease and therefore avoid the use of antibiotics or to improve suboptimal available vaccines is now an European and industry priority. Bovine viral diarrhea virus (BVDV) is an important infectious agent of cattle worldwide that affects herd productivity and reproduction. BVD has been and is an endemic disease in all countries where no systematic eradication and control programs have been established. Under these conditions, approximately 50% of the herds have or have had animals with persistent infection, and approximately 90% of the cattle have been exposed to the virus at some point during their lifetime. Infection with BVDV has a major economic impact, estimated in hundreds of euros per animal for a European hut of around 80 million animals. Aquilón CyL, a leading biotech company, has developed new recombinant vaccine against BVDV using a Virus-Like- Particle patented technology. Aquilón has demonstrated the technical, commercial and regulatory feasibility by the SME instrument phase 1 project (nº 774994). After developing the vaccine to TRL6 stage (pre-industrial prototype with positive activity data), Aquilón will develop one vaccine to TRL8 stage, demonstrating the commercial-scale manufacturing and in-vivo safety, efficacy and DIVA attributes in the target species. This vaccine candidate will be licensed to one or more veterinarian pharmaceutical company that will complete the final field studies required for commercialisation. Our business projections, based on agreements with Development milestones and commercial royalties, show potential for a 5X investment multiplier with a 25% internal rate of return.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BOVLP-BVD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BOVLP-BVD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

SolarGaps (2019)

SolarGaps – Energy generating smart solar window blinds

Read More  

GHOSTWRITERAI (2020)

Artificial Intelligence for Human-Centered Digital Advertising

Read More  

Faze (2019)

Development and commercialisation of a safe, comfortable, adjustable and breathable body protector for dangerous sports industries.

Read More  
lastchecktime (2020-07-11 3:55:29) correctly updated